You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康希諾(06185.HK)重組新冠疫苗入選內地加強針混打 AH股曾急漲逾9%-16%
康希諾生物(06185.HK)新冠疫苗入選內地加強針混打,該股三連升,今早逆市曾重越50天線(154.8元),最多急漲16.6%高見164元遇阻,現報147.1元,續升4.6%,成交230萬股,已接近上周五全日成交量。康希諾生物(688185.SH)三連升,今早股價逆市曾急漲9.8%高見287.99元人民幣,現報274.83元人民幣,續升4.8%。 智飛生物(300122.SZ)的新冠疫苗也入選內地加強針混打,該股今早逆市曾升4.1%高見130.25元人民幣創近兩個月高,現報126.44元人民幣,續升1%。 國家衛健委疾控局副局長吳良有表示,內地新冠疫苗的加強免疫對omicron突破感染具有抑制效果,近日衛健委已開始啟動新冠疫苗加強針混打,重點地區已先行啟動,可選擇康希諾生物或智飛生物疫苗。 康希諾生物公布,旗下重組新冠病毒疫苗「克威莎」獲批用於序貫加強免疫接種,完成全程接種滅活疫苗滿6個月18歲以上的目標人群,可選擇其腺病毒載體疫苗來進行序貫加強免疫接種。 國家衛健委表示,凡全程接種國藥、科興公司滅活疫苗或康希諾生物腺病毒載體疫苗滿六個月的18歲以上的目標人群,可進行一劑次同源加強免疫,也可選擇智飛生物(300122.SZ)旗下智飛龍科馬的重組蛋白疫苗,或康希諾腺病毒載體疫苗進行序貫加強免疫。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account